Acteoside

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

391 Data

Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Acteoside.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Acteoside.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Acteoside.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Acteoside.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Acteoside.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Acteoside.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Acteoside.
Interferon gamma-1b	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Acteoside.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Acteoside.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Acteoside.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Acteoside.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Acteoside.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Acteoside.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Acteoside.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Acteoside.
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Acteoside.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Acteoside.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Acteoside.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Acteoside.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Acteoside.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Acteoside.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Acteoside.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Acteoside.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Acteoside.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Acteoside.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Acteoside.
Daclizumab	The risk or severity of adverse effects can be increased when Daclizumab is combined with Acteoside.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Acteoside.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Acteoside.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Acteoside.
Cladribine	Acteoside may increase the immunosuppressive activities of Cladribine.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Acteoside.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Acteoside.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Acteoside.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Acteoside.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Acteoside.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Acteoside.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Acteoside.
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Acteoside.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Acteoside.
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Acteoside.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Acteoside.
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Acteoside.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Acteoside.
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Acteoside.
Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Acteoside.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Acteoside.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Acteoside.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Acteoside.
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Acteoside.
Teniposide	The risk or severity of adverse effects can be increased when Teniposide is combined with Acteoside.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Acteoside.
Chloramphenicol	The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Acteoside.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Acteoside.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Acteoside.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Acteoside.
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Acteoside.
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Acteoside.
Cyclophosphamide	The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Acteoside.
Vincristine	The risk or severity of adverse effects can be increased when Vincristine is combined with Acteoside.
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Acteoside.
Propylthiouracil	The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Acteoside.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Acteoside.
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Acteoside.
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Acteoside.
Vinblastine	The risk or severity of adverse effects can be increased when Vinblastine is combined with Acteoside.
Fluticasone propionate	The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Acteoside.
Fluocinolone acetonide	The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Acteoside.
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Acteoside.
Imatinib	The risk or severity of adverse effects can be increased when Imatinib is combined with Acteoside.
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Acteoside.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Acteoside.
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Acteoside.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Acteoside.
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Acteoside.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Acteoside.
Daunorubicin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Acteoside.
Irinotecan	The risk or severity of adverse effects can be increased when Irinotecan is combined with Acteoside.
Methimazole	The risk or severity of adverse effects can be increased when Methimazole is combined with Acteoside.
Etoposide	The risk or severity of adverse effects can be increased when Etoposide is combined with Acteoside.
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Acteoside.
Dacarbazine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Acteoside.
Temozolomide	The risk or severity of adverse effects can be increased when Temozolomide is combined with Acteoside.
Penicillamine	The risk or severity of adverse effects can be increased when Penicillamine is combined with Acteoside.
Prednisolone	The risk or severity of adverse effects can be increased when Prednisolone is combined with Acteoside.
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Acteoside.
Mechlorethamine	The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Acteoside.
Azacitidine	The risk or severity of adverse effects can be increased when Azacitidine is combined with Acteoside.
Carboplatin	The risk or severity of adverse effects can be increased when Carboplatin is combined with Acteoside.
Methylprednisolone	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Acteoside.
Dactinomycin	The risk or severity of adverse effects can be increased when Dactinomycin is combined with Acteoside.
Cytarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Acteoside.
Azathioprine	The risk or severity of adverse effects can be increased when Azathioprine is combined with Acteoside.
Doxorubicin	The risk or severity of adverse effects can be increased when Doxorubicin is combined with Acteoside.
Hydroxyurea	The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Acteoside.
Busulfan	The risk or severity of adverse effects can be increased when Busulfan is combined with Acteoside.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Acteoside.
Topotecan	The risk or severity of adverse effects can be increased when Topotecan is combined with Acteoside.
Mercaptopurine	The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Acteoside.
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Acteoside.

Target Protein

Protein kinase C alpha type PRKCA

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0

Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi

1. Pendahuluan & Konsep

2. Sumber Data (Validasi)

3. Algoritma Visualisasi

4. Legenda Visual